The vision of the Oncology Department is to transcend boundaries to lead discovery and its translation into transformative clinical investigations, education, and compassionate patient care that will provide cures for childhood cancer and ensure quality of life across the patient’s lifespan.
Our Oncology faculty are world leaders in identifying novel drugs and treatment modalities, defining the clinical significance of recently discovered genetic abnormalities of cancer cells, understanding mechanisms of cancer development and drug resistance, identifying children at risk for the development of cancer, and understanding and preventing late effects of therapy. We aim to share our unique clinical expertise with colleagues nationally through our many clinical trial consortia and worldwide through our partnership with St. Jude Global. The ultimate goal of our research is to ensure that every child with cancer receives curative therapy and that this therapy allows them the potential for a healthy, long-lasting life.
Dr. Julie R. Park is a pediatric hematologist-oncologist who is interested in developing and advancing new approaches to childhood cancer therapy. Dr. Park received her MD from the University of Vermont and completed residency training in pediatrics at the University of Washington. Dr. Park then completed a fellowship in pediatric hematology/oncology at the University of Washington and Fred Hutchinson Cancer Research Center.
She has been funded as a Fellow for the Leukemia Society of America at Fred Hutchinson Cancer Research Center, and an investigator on NCI and NIH grants. As a Member of the St. Jude Faculty and Chair of the Oncology Department, Dr. Park is interested in discovering the molecular and immunologic vulnerabilities of solid tumor malignancies, such as neuroblastoma, and using this information to inform clinical trials centered on novel therapies for children with relapsed or refractory high-risk tumors.
Department directors
Meaghan Granger, MD Associate Member
Director of Oncology Clinical Medicine
Rebecca Gardner, MD Associate Member
Director of Cellular Therapy Integration
In the news
From the Pediatric Cancer Genome Project and beyond, @stjuderesearch has a long history of genetic discovery. Read about the work of our scientists on the genetics of vulnerabilities, predisposition, molecular groups and data analysis. #StJudeOn
In the news
Stay up-to-date on St. Jude's ongoing effort to end childhood cancer and other catastrophic diseases: @StJudeResearch on X (formerly Twitter).
In the news
DNA isn't destiny, but genetic predispositions do underlie many cancers. St. Jude scientists have gained a nuanced understanding of cancer predisposition and are learning more to help personalize patient therapies. Learn more. #StJudeOn
In the News
Cancer is not a monolith but a landscape of diseases with different drivers. Scientists at St. Jude are leading studies on how understanding molecular groups can advance cancer care. Read about it. #StJudeOn
In the news
Studying genomics means creating big data. Scientists at St. Jude have developed numerous tools and techniques for tackling data with cutting-edge visualizations and analysis. Learn more. #StJudeOn
The Division of Cancer Predisposition promotes cutting-edge clinical, translational and basic research related to genetic predisposition to childhood cancer.
The Division of Cancer Survivorship at St. Jude Children's Research Hospital strives to improve quality of life among adult survivors of pediatric cancer.
The Division of Molecular Oncology investigates the molecular and cellular determinants that lead to tumor formation and that dictate cellular responses to cytotoxic stresses.
The Neuro-Oncology division at St. Jude works advances knowledge related to the etiology, biology, treatment, and eventually cures of brain tumors in children
The Division of Quality of Life & Palliative Care provides patient and family-centered care promoting holistic symptom management, care coordination and support to optimize quality of life.
The Solid Tumor division develops and tests novel therapeutics for the treatment of pediatric solid tumors, particularly those at high risk of treatment failure
Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy
Ehrhardt et al. Journal of Clinical Oncology, 2024
Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis.
Keenan et al. Blood, 2024
Care Models and Barriers to Long-Term Follow-Up Care Among Childhood Cancer Survivors and Health Care Providers in Asia: A Literature Review
Cai et al. JCO Glob Oncol, 2024
Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions.
Cobaleda et al. Cancer Discovery, 2024
Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion
Ma et al. Leukemia, 2024
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital
Gaietto et al. Cancer Chemother Pharmacol
Health Care Transitions Among Adolescents and Young Adults With Cancer
Ehrhardt et al. J Clin Oncol, 2024
Mind the Gap: A Multiprong Approach to Minimizing the Gap in Outcomes Among Adolescents and Young Adults With Cancer
Hudson et al. J Clin Oncol, 2024
Genomes for Nurses: Understanding and Overcoming Barriers to Nurses Utilizing Genomics.
Hines-Dowell et al. J Pediatr Hematol Oncol Nurs, 2024
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.
Das et al. Cancer Discov, 2024
COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma
Hashmi et al. JAMA Netw Open, 2024
The St. Jude Children's Research Hospital After Completion of Therapy Clinic
Hudson. J Cancer Surviv, 2024
Adult-onset cancer predisposition syndromes in children and adolescents - to test or not to test?
Kratz et al. Clin Cancer Res, 2024
Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
Suwannaying et al. Br J Haematol, 2024
Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard et al. J Natl Cancer Inst, 2024
Cough, Neck Pain, and Right Facial Paralysis in a 14-year-old with Autism
Hu et al. Pediatr Rev, 2024
Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
Leung et al. Leukemia, 2024
PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
Searcy et al. Nat Commun, 2023
A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics
Lee et al, Geeleher. Nature Comm, 2023
Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL
Lee et al. J Clin Oncol, 2023
Editorial: Recent advances in peptide informatics: Challenges and opportunities
Kumar R et al. Front Bioinform 2023
Integration of palliative care in hematopoietic cell transplant: Pediatric patient and parent needs and attitudes
Levine DR et al. J Pain Symptom Manage 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administr
Pearson ADJ et al. Eur J Cancer 2023
Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia
Li X et al. Clin Lymphoma Myeloma Leuk 2023
A survey of pediatric palliative care and pain management specialists
Cuviello A et al. Am J Hosp Palliat Care 2023
Constitutional balanced translocations involving SMARCB1: A rare cause of rhabdoid tumor predisposition syndrome
Blackburn et al. Genes Chromosomes Cancer, 2024
Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
Karol SE et al.. Blood Adv 2023
A molecular blueprint to targeting ALK gene fusions in glioblastoma
Mack SC et al. Clin Cancer Res 2023
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries.
Zheng Y et al. Haematologica 2023
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma
Purvis KN et al. Cancer Chemother Pharmacol 2023
Optimizing pediatric leukemia care in countries with limited resources
Ribeiro RC et al. J Clin Oncol 2023
Germline genomic findings in children and young adults with melanocytic tumors.
Nagel MB, et al. Pediatr Blood Cancer, 2023
Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
